Rinaldi D A, Lippman S M, Burris H A, Chou C, Von Hoff D D, Hong W K
Brooke Army Medical Center, San Antonio, TX 78234.
Anticancer Drugs. 1993 Feb;4(1):33-6. doi: 10.1097/00001813-199302000-00004.
The combination of interferon (IFN)-alpha 2a and 13-cis-retinoic acid (13-cRA) has demonstrated significant antitumor activity in patients with advanced squamous cell cancer of the skin and cervix. We performed a prospective phase II trial of this combination in patients with locally advanced or metastatic squamous cell lung cancer. Twenty-one patients were enrolled on the study. All patients were evaluable for toxicity and 17 were evaluable for response, four with locally advanced and 13 with metastatic disease. One partial response was obtained in a patient with locally advanced disease. Toxicity consisted mainly of constitutional side effects (fatigue, anorexia), which resulted in eight patients coming off-study. The combination of IFN-alpha 2a and 13-cRA is unlikely to exhibit significant clinical activity in patients with metastatic squamous cell lung cancer, but activity in patients with locally advanced disease has not been excluded.
干扰素（IFN）-α2a与13-顺式维甲酸（13-cRA）联合使用已在晚期皮肤和宫颈鳞状细胞癌患者中显示出显著的抗肿瘤活性。我们对局部晚期或转移性肺鳞状细胞癌患者进行了该联合方案的前瞻性II期试验。21名患者入组本研究。所有患者均可评估毒性，17名患者可评估疗效，其中4名患有局部晚期疾病，13名患有转移性疾病。一名局部晚期疾病患者获得部分缓解。毒性主要包括全身副作用（疲劳、厌食），导致8名患者退出研究。IFN-α2a与13-cRA联合使用在转移性肺鳞状细胞癌患者中不太可能表现出显著的临床活性，但尚未排除在局部晚期疾病患者中的活性。
